Jardiance and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

How Common Is This Drug Combination?

Patients with type 2 diabetes and cardiovascular disease are routinely prescribed both an SGLT2 inhibitor and a statin. That overlap is not coincidental. Type 2 diabetes carries a two- to four-fold increase in atherosclerotic cardiovascular disease risk compared with the general population, according to the American Heart Association [1]. Rosuvastatin is one of the most prescribed statins globally, and Jardiance (empagliflozin) has become a first-line agent after the 2023 ADA Standards of Care recommended SGLT2 inhibitors for patients with T2DM and established heart disease or high cardiovascular risk [2].

The result: millions of patients now take these two drugs together. Clinicians and patients alike search for clear answers about whether this combination is safe.

The Short Answer: No Clinically Significant Interaction

Empagliflozin and rosuvastatin do not share a pharmacokinetic pathway that would cause one drug to raise or lower the blood concentration of the other to a clinically important degree. No dose adjustment is recommended in the Jardiance FDA prescribing information for concurrent rosuvastatin use [3]. The same holds for the rosuvastatin (Crestor) FDA label, which identifies OATP inhibitors such as cyclosporine, not SGLT2 inhibitors, as the relevant interaction partners [4].

This does not mean there is zero theoretical overlap. Understanding why the overlap is negligible requires a look at how each drug is actually processed.

Pharmacokinetics of Empagliflozin

Absorption and Distribution

Empagliflozin reaches peak plasma concentration (Tmax) in approximately 1.5 hours after oral dosing. Oral bioavailability is about 78%. It is roughly 86% protein-bound in plasma, primarily to albumin [3].

Metabolism and Elimination

The liver metabolizes empagliflozin primarily through glucuronidation. The responsible enzymes are UGT1A3, UGT1A8, UGT2B7, and UGT1A9. CYP450 enzymes contribute negligibly to empagliflozin clearance. About 54% of an oral dose is excreted in feces and 41% in urine, largely as unchanged drug or glucuronide conjugates [3].

This metabolic profile matters for drug interactions. Because empagliflozin is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, it cannot raise or lower plasma levels of drugs that depend on those enzymes, including the minor CYP2C9 metabolism of rosuvastatin.

P-glycoprotein and BCRP

Empagliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but it does not act as a meaningful inhibitor of either transporter at clinically relevant concentrations [3]. BCRP is also a significant efflux transporter for rosuvastatin. Because empagliflozin does not inhibit BCRP at therapeutic doses, it does not impede rosuvastatin efflux in a way that would increase rosuvastatin systemic exposure.

Pharmacokinetics of Rosuvastatin

Hepatic Uptake via OATP Transporters

Rosuvastatin's pharmacokinetics are dominated by hepatic uptake transporters, specifically OATP1B1 (encoded by SLCO1B1) and OATP1B3. These organic anion-transporting polypeptides carry rosuvastatin from portal blood into hepatocytes, which is where it exerts its HMG-CoA reductase inhibition [4].

Drugs that potently inhibit OATP1B1/1B3, including cyclosporine, atazanavir/ritonavir, and gemfibrozil, can raise rosuvastatin AUC by two- to seven-fold, meaningfully increasing myopathy risk. Empagliflozin is not a recognized OATP1B1 or OATP1B3 inhibitor. No dedicated clinical DDI study has shown empagliflozin to alter rosuvastatin hepatic uptake.

CYP2C9 and BCRP

About 10% of rosuvastatin undergoes CYP2C9-mediated metabolism to N-desmethyl rosuvastatin, a less active metabolite. The majority of systemic clearance occurs via biliary excretion facilitated by BCRP (ABCG2). As noted, empagliflozin does not inhibit CYP2C9 or BCRP at therapeutic concentrations, so neither pathway is disrupted [3][4].

SLCO1B1 Genotype: The Real Myopathy Determinant

The single-nucleotide polymorphism rs4149056 in SLCO1B1 (the gene encoding OATP1B1) is associated with reduced hepatic uptake of rosuvastatin and, consequently, higher plasma exposure. Patients who carry the c.521T>C variant may have rosuvastatin AUC values 1.6 to 2.4 times higher than wild-type carriers, increasing myopathy risk independent of any co-medication [5]. Pharmacogenomic testing for SLCO1B1 is now endorsed by the Clinical Pharmacogenomics Implementation Consortium (CPIC). This genetic factor, not empagliflozin co-administration, represents the most clinically relevant driver of variable rosuvastatin exposure.

Dedicated Drug Interaction Data

What the FDA Labels Say

The Jardiance prescribing information lists drug interaction studies performed with multiple co-medications including warfarin, verapamil, ramipril, simvastatin, metformin, and hydrochlorothiazide. Simvastatin, not rosuvastatin, was tested directly in a dedicated PK study. Co-administration of empagliflozin 25 mg with simvastatin 40 mg did not produce a clinically meaningful change in simvastatin or simvastatin acid AUC [3]. Because rosuvastatin uses a different and less CYP-dependent elimination pathway than simvastatin, the theoretical risk of interaction with empagliflozin is, if anything, lower than that seen with simvastatin.

Evidence From Large Outcome Trials

The EMPA-REG OUTCOME trial (N=7,020) randomized patients with T2DM and established cardiovascular disease to empagliflozin 10 mg, empagliflozin 25 mg, or placebo, all on top of standard-of-care therapy [6]. At baseline, 76.6% of participants were taking a statin. Rosuvastatin was among the statins represented. The trial ran for a median of 3.1 years. No safety signal related to statin-drug interaction was identified; rates of adverse muscle events did not differ between empagliflozin and placebo arms in the trial's safety analysis [6].

The EMPEROR-Reduced trial (N=3,730) and EMPEROR-Preserved trial (N=5,988) similarly enrolled large proportions of statin users without reporting a statin-specific interaction signal for empagliflozin [7][8].

These large trial populations do not replace a dedicated empagliflozin-rosuvastatin PK crossover study, but they provide meaningful real-world denominator data across tens of thousands of patient-years of concurrent use.

Pharmacodynamic Considerations

Volume Depletion and Renal Function

Empagliflozin induces osmotic diuresis through glucosuria, reducing plasma volume by approximately 5 to 7% within the first weeks of therapy [6]. This effect is the likely mechanism behind SGLT2 inhibitors' cardiorenal benefits but can also lower blood pressure and reduce renal perfusion.

Rosuvastatin does not directly affect volume status or renal hemodynamics. However, volume depletion from any cause may modestly reduce glomerular filtration rate (GFR), and rosuvastatin is renally excreted to a small degree (about 28% of an oral dose). In patients with pre-existing chronic kidney disease, a clinically meaningful drop in GFR induced by volume depletion might slow rosuvastatin clearance marginally. This is more theoretical than documented, but it supports routine monitoring of renal function in patients starting empagliflozin who are already on a statin.

Glucose Lowering and Lipid Metabolism

SGLT2 inhibition shifts substrate utilization toward fat oxidation and ketone production. Some analyses have shown small increases in LDL-C with SGLT2 inhibitors. In a pooled analysis of empagliflozin trials, LDL-C increased by approximately 1 to 2 mg/dL vs. Placebo over 24 weeks [9]. This modest rise does not negate the cardiovascular benefit of empagliflozin, and concurrent rosuvastatin therapy more than offsets any LDL-raising effect. Clinicians should review the lipid panel at the 3-month mark after starting empagliflozin to confirm the statin dose remains adequate.

Clinical Monitoring Protocol

Baseline Assessment Before Starting the Combination

Before initiating empagliflozin in a patient already taking rosuvastatin, clinicians should document:

• Serum creatinine and eGFR (empagliflozin is contraindicated when eGFR <20 mL/min/1.73 m² for T2DM indication and carries reduced efficacy at eGFR <45) [3]
• Blood pressure and volume status
• Fasting lipid panel and HbA1c
• Current rosuvastatin dose and any prior myopathy history
• Concomitant medications that are known OATP inhibitors (cyclosporine, gemfibrozil), which do interact with rosuvastatin and may require dose reduction independently of empagliflozin

Ongoing Monitoring

Renal function and electrolytes should be checked at 4 to 12 weeks after empagliflozin initiation and then at least annually, per the Jardiance label [3]. The lipid panel should be reviewed at approximately 3 months, then every 6 to 12 months. Creatine kinase (CK) testing is not routinely recommended in the absence of muscle symptoms; however, a patient who reports unexplained muscle pain, weakness, or dark urine while on rosuvastatin should have CK measured promptly regardless of empagliflozin co-administration.

When to Lower the Rosuvastatin Dose

The rosuvastatin label specifies dose limits with particular co-medications. The 40 mg dose is reserved for patients who have not achieved their LDL goal on 20 mg and who are not at increased risk of myopathy. The dose cap for Asian patients remains 20 mg daily due to higher average exposure from pharmacogenomic variability [4]. None of these caps are triggered by empagliflozin. The decision to reduce rosuvastatin dose should be driven by tolerability, renal function, or co-administration of a true OATP inhibitor, not by SGLT2 inhibitor use.

Patient Counseling Points

What to Tell the Patient Starting Both Drugs

Patients prescribed both Jardiance and rosuvastatin deserve a concise, honest explanation:

1. The two drugs do not interfere with each other's blood levels in a meaningful way. Taking them together does not raise the risk of rosuvastatin-related muscle damage compared with taking rosuvastatin alone.
2. Jardiance can cause increased urination and, in some patients, lightheadedness. Drinking adequate water is a practical safeguard, particularly in hot weather or during illness.
3. Muscle soreness is a known side effect of statins including rosuvastatin. The presence of Jardiance does not change that risk, but patients should still report unexplained muscle pain, weakness, or brown urine to their prescriber promptly.
4. Both medications work best as long-term therapies. A 2023 analysis published in the Journal of the American College of Cardiology estimated that stopping an SGLT2 inhibitor after an MI increased 30-day readmission risk by 22% [10]. Discontinuation should not happen without physician guidance.

Adherence Strategies

Patients with diabetes and cardiovascular disease take an average of 5 to 8 medications daily, a burden that contributes to the 50% non-adherence rate reported at 12 months for chronic disease medications [11]. Prescribing empagliflozin and rosuvastatin as once-daily morning medications with a fixed daily habit anchor, such as breakfast, supports co-administration and simplifies the regimen.

Special Populations

Patients With Chronic Kidney Disease

Empagliflozin received FDA approval for CKD (eGFR 20 to 44 mL/min/1.73 m²) at a dose of 10 mg once daily based on the EMPA-KIDNEY trial (N=6,609), which showed a 28% reduction in the composite of kidney disease progression or cardiovascular death vs. Placebo [12]. Rosuvastatin dose adjustments are also warranted in severe renal impairment (eGFR <30 mL/min/1.73 m²), where the recommended starting dose is 5 mg and the ceiling is 10 mg daily [4]. The interaction between empagliflozin and rosuvastatin in this population remains pharmacokinetically benign, but both drugs require renal-function-based dose titration independently.

Elderly Patients

Patients over 75 are more susceptible to volume depletion from empagliflozin and may have baseline muscle mass loss that lowers the threshold for statin-induced myopathy symptoms. The clinical approach is not to avoid the combination but to start empagliflozin at 10 mg and review rosuvastatin dose (many elderly patients do not require high-intensity statin therapy if their baseline LDL is already well-controlled) and to have a low threshold for checking CK when muscle complaints arise.

Patients With Heart Failure

In EMPEROR-Reduced, patients receiving empagliflozin 10 mg showed a 25% relative risk reduction in the composite of cardiovascular death or HF hospitalization vs. Placebo over a median of 16 months [7]. Statin use in HF patients is complex: statins have not been shown to reduce mortality in HF with reduced ejection fraction in CORONA or GISSI-HF trials, but patients with ischemic etiology HF are typically maintained on statins for atherosclerosis risk reduction. Co-administration of empagliflozin with rosuvastatin in this population follows the same benign pharmacokinetic picture described above.

Summary of Interaction Classification

The table below places the Jardiance-rosuvastatin pair in context alongside known high-risk rosuvastatin interactions:

| Co-medication | Interaction Mechanism | Rosuvastatin AUC Change | Clinical Action | |---|---|---|---| | Cyclosporine | OATP1B1/1B3 inhibition | Up to +7-fold | Limit rosuvastatin to 5 mg/day | | Gemfibrozil | OATP + CYP2C8 inhibition | +2-fold | Avoid combination | | Atazanavir/ritonavir | OATP1B1 inhibition | +3-fold | Limit rosuvastatin to 10 mg/day | | Empagliflozin | None identified | No clinically significant change | No dose adjustment needed |